Idorsia and Viatris in R&D collaboration

 

• Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.
• Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.
• Viatris and Idorsia will both contribute to the development costs for both programs.
• Includes future optionality to expand collaboration with additional pipeline assets.
• Combines Viatris’ financial strength and worldwide operational infrastructure with Idorsia’s proven, highly productive drug development team and innovative engine.
  

https://www.globenewswire.com/news-release/2024/02/28/2836599/0/en/Idorsia-and-Viatris-enter-into-a-significant-global-research-and-development-collaboration.html